Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that the Company will present data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, in advanced solid tumor patients in an oral plenary session at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium taking place November 13-16 in Dublin. The presentation will include data on safety, pharmacokinetics and proof-of-mechanism. These data will be the first clinical data presented on a selective CDK7 inhibitor, marking a significant milestone in the development of selective CDK7 inhibitors for the treatment of cancer.
In additional poster presentations, Syros will present new preclinical data on the mechanistic rationale for SY-1365 in combination with carboplatin in ovarian cancer; the first preclinical data on its oral CDK7 inhibitor program; and the discovery of drug targets and patient subsets from its analysis of the super-enhancer landscape in ovarian cancer.
The abstract for the oral presentation on SY-1365 will remain under embargo until the day of the presentation. The abstracts for the poster presentations are now available online on the EORTC-NCI-AACR conference website at https://www.ecco-org.eu/events/ENA2018.
Details on the oral presentation are as follows:
Presentation Title: Proof-of-Mechanism Based on Target Engagement and Modulation of Gene Expression Following Treatment with SY-1365, a First-in-Class Selective CDK7 Inhibitor in Phase 1 Patients with Advanced Cancer Session Date & Time: Thursday, November 15, 14:30-15:45 GMT (9:30-10:45 a.m. ET) Presentation Time: 15:30-15:45 GMT (10:30-10:45 a.m. ET) Session Title: Plenary Session 6: Proffered Papers Presenter: Dejan Juric, M.D., Massachusetts General Hospital Abstract Number: 11 Location: Auditorium, The Convention Centre Dublin
Details on the poster presentations are as follows:
Presentation Title: SY-1365, a selective CDK7 inhibitor, enhances carboplatin activity in ovarian cancer cell lines and xenografts, and transcriptionally inhibits homologous recombination repair (HRR) genes Date & Time: Tuesday, November 13, 12:00-19:00 GMT (7:00 a.m.-2:00 p.m. ET) Session Title: Poster Session: DNA Repair Modulation Presenter: Liv Johannessen, Ph.D., Syros Abstract Number: 50 Location: PB-001, Exhibition Hall, The Convention Centre Dublin
Presentation Title: An oral and selective CDK7 inhibitor demonstrates substantial anti-tumor effect in breast and ovarian cancer models Date & Time: Tuesday, November 13, from 12:00-19:00 GMT (7:00 a.m.-2:00 p.m. ET) Session Title: Poster Session: Molecular Targeted Agents “ PART 1 Presenter: Claudio Chuaqui, Ph.D., Syros Abstract Number: 96 Location: PB-047, Exhibition Hall, The Convention Centre Dublin
Presentation Title: Super-enhancer landscapes of ovarian cancer reveal novel epigenomic subtypes and targets Date & Time: Friday, November 16, from 10:00-14:00 GMT (5:00-9:00 a.m. ET) Session Title: Poster Session: Molecular Targeted Agents “ PART II Presenter: Matthew Eaton, Ph.D., Syros Abstract Number: 400 Location: PB-063, Exhibition Hall, The Convention Centre Dublin
About Syros Pharmaceuticals Syros is pioneering the understanding of the non-coding regulatory region of the genome to advance a new wave of medicines that control the expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros lead drug candidates are SY-1425, a selective RARÎ± agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with ovarian and breast cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.
Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the presentation of data at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium; the potential benefits of CDK7 inhibition and of SY-1365, alone or in combination with carboplatin; the ability to identify novel targets or patient subpopulations in ovarian cancer; and the benefits of Syros gene control platform. The words ˜˜anticipate, ˜˜believe, ˜˜continue, ˜˜could, ˜˜estimate, ˜˜expect, hope, ˜˜intend, ˜˜may, ˜˜plan, ˜˜potential, ˜˜predict, ˜˜project, ˜˜target, ˜˜should, ˜˜would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including Syros ability to: advance the development of its programs, including SY-1425 and SY-1365, under the timelines it projects in current and future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; replicate scientific and non-clinical data in clinical trials; successfully develop a companion diagnostic test to identify patients with the RARA and IRF8 biomarkers; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and maintain collaboration agreements with third parties, including its ability to perform under the collaboration agreement with Incyte; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified personnel; and successfully execute on its business strategies; risks described under the caption Risk Factors in Syros Annual Report on Form 10-K for the year ended December 31, 2017, as updated in its Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2018, each of which is on file with the Securities and Exchange Commission; and risks described in other filings that Syros makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Syros expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.